Global Allergy Reach Inmunotek already sells in Spain and over 50 other countries through subsidiaries, sales offices, and exclusive distributors, indicating a broad international footprint and established distribution channels—opportunity to expand or optimize partnerships in regions with rising allergy and immune-related treatment demand.

Therapeutic Vaccine Focus The company specializes in therapeutic vaccines for allergies, infectious diseases, and cancer, suggesting potential cross-sell opportunities with existing vaccine platforms, as well as partnerships for co-development or licensing in niche indications within immunotherapy.

GMP Manufacturing Two GMP-certified production centers in Madrid area demonstrate proven manufacturing capability and compliance, positioning Inmunotek as a reliable partner for contract manufacturing, fill-finish services, or scale-up collaborations for external programs.

Awarded Innovator Recognition as a National Innovation Award recipient signals a track record of innovation and potential for collaboration on advanced formulations, novel delivery methods, or technology licenses that can be offered to healthcare buyers seeking cutting-edge solutions.

Financial Size & Growth Revenue in the $50M–$100M range and prior growth recognition imply a solid mid-market profile with appetite for strategic partnerships, distribution deals, or co-marketing arrangements with larger pharma players seeking expansion in immunology-based therapies.